Compare PDS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | DSGN |
|---|---|---|
| Founded | 1951 | 2017 |
| Country | Canada | United States |
| Employees | 5245 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 819.6M |
| IPO Year | 1998 | 2021 |
| Metric | PDS | DSGN |
|---|---|---|
| Price | $96.68 | $11.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $122.33 | $15.25 |
| AVG Volume (30 Days) | 95.1K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.95 | $3.33 |
| 52 Week High | $103.80 | $17.25 |
| Indicator | PDS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 40.09 |
| Support Level | $83.72 | $9.25 |
| Resistance Level | $103.13 | $13.54 |
| Average True Range (ATR) | 3.05 | 1.32 |
| MACD | 0.41 | -0.52 |
| Stochastic Oscillator | 59.73 | 16.83 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.